Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
LOS ANGELES, March 10, 2016 -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Michael Step, Chief Executive Officer, will present a corporate overview at the 28th Annual ROTH Conference on Tuesday, March 15, 2016.
Event: 28th Annual ROTH Conference
Date: Tuesday, March 15, 2016
Time: 12:30-1:00 p.m. PT
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.
Investor Contact: David Burke [email protected] (646) 536-7009
